Skip to main content
Premium Trial:

Request an Annual Quote

Cambridge Epigenetix, NuGen Form Epigenetic Sequencing Partnership

NEW YORK (GenomeWeb) – Cambridge Epigenetix and NuGen Technologies have partnered to integrate Cambridge's TrueMethyl technology for oxidative bisulfite sequencing with NuGen's sequencing library preparation kits.

The companies said that the agreement will enable Cambridge to focus on its epigenetic biomarker discovery programs, both in house and in partnership with biopharma companies, while strengthening NuGen's whole-genome and targeted enrichment systems for epigenetic sequencing.

In addition, the combined technologies will broaden the scope of accessible samples for the detection of epigenetic DNA modifications such as 5-hydroxymethylcytosine and 5-methylcytosine, which play important roles in gene regulation in disease occurrence and progression.

New products resulting from this partnership are anticipated by the end of the year and will be available directly from NuGen, the companies said.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.